AACAP Endorses the Inclusion of Methylphenidate in the WHO Model Lists of Essential Medicines.
Samuele CorteseDavid CoghillGregory W MattinglyLuis Augusto RohdeRobyn P ThomTimothy E WilensIan C K WongStephen V FaraonePublished in: Journal of the American Academy of Child and Adolescent Psychiatry (2024)
Despite decades of clinical use and a large body of evidence, the WHO continues to exclude methylphenidate for attention-deficit/hyperactivity disorder (ADHD) from its EML. 1 The exclusion of methylphenidate has dire implications for millions of individuals with ADHD worldwide, especially those living in low and low-middle income countries (LMIC), where governmental decisions to make medicines available are contingent on EML listing.